Terms: = Lymphoma AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874
164 results:
1. Evaluation of Immunohistochemical Expression of ALK-1 in Gliomas, WHO Grade 4 and Its Correlation with idh1-R132H Mutation Status.
Khairy RA; Momtaz EM; Abd El Aziz AM; Shibel PEE
Asian Pac J Cancer Prev; 2024 Jan; 25(1):317-323. PubMed ID: 38285799
[TBL] [Abstract] [Full Text] [Related]
2. Comparative evaluation of
Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
[TBL] [Abstract] [Full Text] [Related]
3. Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
Sutter T; Schittenhelm M; Volken T; Lehmann T
Hematology; 2023 Dec; 28(1):2206694. PubMed ID: 38078486
[TBL] [Abstract] [Full Text] [Related]
4. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and idh inhibitors.
Madero-Marroquin R; DuVall AS; Saygin C; Wang P; Gurbuxani S; Larson RA; Stock W; Patel AA
Br J Haematol; 2024 Apr; 204(4):1238-1242. PubMed ID: 38073116
[TBL] [Abstract] [Full Text] [Related]
5. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
6. SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic Malignancies.
Forsberg M; Konopleva M
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):1-14. PubMed ID: 38007372
[TBL] [Abstract] [Full Text] [Related]
7. BCL2A1 is associated with tumor-associated macrophages and unfavorable prognosis in human gliomas.
Gao L; Ye Z; Peng S; Lei P; Song P; Li Z; Zhou L; Hua Q; Cheng L; Wei H; Liu J; Cai Q
Aging (Albany NY); 2023 Oct; 15(20):11611-11638. PubMed ID: 37889551
[TBL] [Abstract] [Full Text] [Related]
8. Intraoperative Integrated Diagnostic System for Malignant Central Nervous System Tumors.
Hayashi T; Tateishi K; Matsuyama S; Iwashita H; Miyake Y; Oshima A; Honma H; Sasame J; Takabayashi K; Sugino K; Hirata E; Udaka N; Matsushita Y; Kato I; Hayashi H; Nakamura T; Ikegaya N; Takayama Y; Sonoda M; Oka C; Sato M; Isoda M; Kato M; Uchiyama K; Tanaka T; Muramatsu T; Miyake S; Suzuki R; Takadera M; Tatezuki J; Ayabe J; Suenaga J; Matsunaga S; Miyahara K; Manaka H; Murata H; Yokoyama T; Tanaka Y; Shuto T; Ichimura K; Kato S; Yamanaka S; Cahill DP; Fujii S; Shankar GM; Yamamoto T
Clin Cancer Res; 2024 Jan; 30(1):116-126. PubMed ID: 37851071
[TBL] [Abstract] [Full Text] [Related]
9.
Babakhanlou R; DiNardo C; Borthakur G
Leuk Lymphoma; 2023; 64(11):1733-1741. PubMed ID: 37462435
[TBL] [Abstract] [Full Text] [Related]
10. Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
Borate U; Yang F; Press R; Ruppert AS; Jones D; Caruthers S; Zhao W; Vergilio JA; Pavlick DC; Juckett L; Norris B; Bucy T; Burd A; Stein EM; Patel P; Baer MR; Stock W; Schiller G; Blum W; Kovacsovics T; Litzow M; Foran J; Heerema NA; Rosenberg L; Marcus S; Yocum A; Stefanos M; Druker B; Byrd JC; Levine RL; Mims A
Blood Adv; 2023 Oct; 7(20):6048-6054. PubMed ID: 37459200
[TBL] [Abstract] [Full Text] [Related]
11. Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3.
Patel SA
Leuk Lymphoma; 2023 Sep; 64(9):1503-1513. PubMed ID: 37328939
[TBL] [Abstract] [Full Text] [Related]
12. Myeloid sarcoma with
Ramia de Cap M; Wu LP; Hirt C; Pihan GA; Patel SS; Tam W; Bueso-Ramos CE; Kanagal-Shamanna R; Raess PW; Siddon A; Narayanan D; Morgan EA; Pinkus GS; Mason EF; Hsi ED; Rogers HJ; Toth L; Foucar K; Hurwitz SN; Bagg A; Rets A; George TI; Orazi A; Arber DA; Hasserjian RP; Weinberg OK;
Leuk Lymphoma; 2023 May; 64(5):972-980. PubMed ID: 36960680
[TBL] [Abstract] [Full Text] [Related]
13. SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It.
Patel AA; Odenike O
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):303-309. PubMed ID: 36907766
[TBL] [Abstract] [Full Text] [Related]
14. Gene Mutations and Targeted Therapies of Myeloid Sarcoma.
Fu L; Zhang Z; Chen Z; Fu J; Hong P; Feng W
Curr Treat Options Oncol; 2023 Apr; 24(4):338-352. PubMed ID: 36877373
[TBL] [Abstract] [Full Text] [Related]
15. Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.
Aldea M; Tagliamento M; Bayle A; Vasseur D; Vergé V; Marinello A; Danlos FX; Blanc-Durand F; Bernard E; Cerbone L; Mosele MF; Renneville A; Hadoux J; Loriot Y; Sakkal M; Vozy A; Sarkozy C; Smolenschi C; Nicotra C; Martin-Romano P; Boccon-Gibod C; Habza W; Lazarovici J; Ponce S; Hollebecque A; Marzac C; Lacroix L; Barlesi F; André F; Besse B; Rouleau E; Italiano A; Micol JB
JCO Precis Oncol; 2023 Mar; 7():e2200583. PubMed ID: 36862966
[TBL] [Abstract] [Full Text] [Related]
16. ALK Gene Mutation and ALK Protein Expression in Advanced Neuroblastoma and the Potential Value in Risk Stratification in Fine-Needle Aspiration Biopsy Samples.
Bhardwaj N; Rohilla M; Gautam U; Trehan A; Bansal D; Kakkar N; Srinivasan R
Am J Clin Pathol; 2023 Apr; 159(4):407-415. PubMed ID: 36812383
[TBL] [Abstract] [Full Text] [Related]
17. Transcriptional Profiling Identifies Prognostic Gene Signatures for Conjunctival Extranodal Marginal Zone lymphoma.
Wolf J; Reinhard T; Hajdu RI; Schlunck G; Auw-Haedrich C; Lange C
Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671500
[TBL] [Abstract] [Full Text] [Related]
18. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.
Horbinski C; Nabors LB; Portnow J; Baehring J; Bhatia A; Bloch O; Brem S; Butowski N; Cannon DM; Chao S; Chheda MG; Fabiano AJ; Forsyth P; Gigilio P; Hattangadi-Gluth J; Holdhoff M; Junck L; Kaley T; Merrell R; Mrugala MM; Nagpal S; Nedzi LA; Nevel K; Nghiemphu PL; Parney I; Patel TR; Peters K; Puduvalli VK; Rockhill J; Rusthoven C; Shonka N; Swinnen LJ; Weiss S; Wen PY; Willmarth NE; Bergman MA; Darlow S
J Natl Compr Canc Netw; 2023 Jan; 21(1):12-20. PubMed ID: 36634606
[TBL] [Abstract] [Full Text] [Related]
19. Tumor mutation burden involving epigenetic regulatory genes and the RhoA GTPase predicts overall survival in nodal mature T-cell lymphomas.
de Pádua Covas Lage LA; Culler HF; Barreto GC; Reichert CO; Levy D; de Oliveira Costa R; Rocha V; Pereira J
Clin Epigenetics; 2022 Dec; 14(1):180. PubMed ID: 36536430
[TBL] [Abstract] [Full Text] [Related]
20. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with
Bewersdorf JP; Patel KK; Goshua G; Shallis RM; Podoltsev NA; Stahl M; Stein EM; Huntington SF; Zeidan AM
Leuk Lymphoma; 2023 Feb; 64(2):454-461. PubMed ID: 36493798
[TBL] [Abstract] [Full Text] [Related]
[Next]
